DE60335279D1 - Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem - Google Patents
Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystemInfo
- Publication number
- DE60335279D1 DE60335279D1 DE60335279T DE60335279T DE60335279D1 DE 60335279 D1 DE60335279 D1 DE 60335279D1 DE 60335279 T DE60335279 T DE 60335279T DE 60335279 T DE60335279 T DE 60335279T DE 60335279 D1 DE60335279 D1 DE 60335279D1
- Authority
- DE
- Germany
- Prior art keywords
- new method
- carrier system
- lipid membrane
- therapeutic compounds
- cationic carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39124602P | 2002-06-26 | 2002-06-26 | |
US39124402P | 2002-06-26 | 2002-06-26 | |
US39124502P | 2002-06-26 | 2002-06-26 | |
EP02018724A EP1374864A1 (de) | 2002-06-26 | 2002-08-21 | Amphiphile, Taxane enthaltende Zusammensetzungen |
EP02018907A EP1393719A1 (de) | 2002-08-23 | 2002-08-23 | Camptothecin-Carboxylat Formulierungen |
EP03004744 | 2003-03-04 | ||
PCT/EP2003/006765 WO2004002455A1 (en) | 2002-06-26 | 2003-06-26 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60335279D1 true DE60335279D1 (de) | 2011-01-20 |
Family
ID=43302284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60335279T Expired - Lifetime DE60335279D1 (de) | 2002-06-26 | 2003-06-26 | Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem |
Country Status (8)
Country | Link |
---|---|
US (2) | US20050181038A1 (de) |
EP (1) | EP1553924B1 (de) |
JP (1) | JP2005534718A (de) |
AT (1) | ATE490763T1 (de) |
AU (1) | AU2003249882B2 (de) |
CA (1) | CA2492080A1 (de) |
DE (1) | DE60335279D1 (de) |
WO (1) | WO2004002455A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8029795B2 (en) * | 1999-12-30 | 2011-10-04 | Gwathmey, Inc. | Targeted iron chelator delivery system |
CA2542217C (en) * | 2003-10-15 | 2018-03-27 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
EP1761248B1 (de) * | 2004-03-19 | 2012-05-23 | Rodos BioTarget GmbH | Kohlehydrat-derivatisierte liposome gegen zelluläre kohlehydrat-erkennungsdomänen von ctl/ctld-lektinen und intrazelluläre freisetzung von therapeutischen wirkverbindungen |
AU2006243337B2 (en) | 2005-05-04 | 2011-09-29 | Syncore Biotechnology Co., Ltd | Method of administering a cationic liposomal preparation comprising paclitaxel |
US20070264200A1 (en) * | 2005-11-14 | 2007-11-15 | Scott Small | Mouse MRI for drug screening |
CA2922029C (en) | 2006-03-22 | 2017-11-28 | Medigene Ag | A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent |
DE602007007618D1 (de) * | 2006-05-18 | 2010-08-19 | Univ Muenchen L Maximilians | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis |
WO2008052766A2 (en) * | 2006-11-03 | 2008-05-08 | Medigene Ag | Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
US8263117B2 (en) | 2007-02-09 | 2012-09-11 | National University Corporation NARA Institute of Science and Technology | C70-containing liposome, method for producing the same, and use of the same |
US9814672B2 (en) * | 2007-03-09 | 2017-11-14 | Susan T. Laing | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi |
EP3494964B1 (de) * | 2007-05-14 | 2021-04-07 | Konica Minolta Holdings, Inc. | Liposom und verfahren zur herstellung des liposoms |
US9492417B2 (en) | 2008-08-21 | 2016-11-15 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
US20130209368A1 (en) * | 2010-09-09 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Near infrared fluorescent particles and uses thereof |
CN102133404B (zh) * | 2011-03-23 | 2013-01-16 | 成都诺恩生物科技有限公司 | 一种肿瘤靶向治疗药物载体、其制备方法及其应用 |
US9415110B1 (en) | 2013-05-08 | 2016-08-16 | The Arizona Board of Regents on behalf of the Univeristy of Arizona | Method and compositions for targeted drug delivery to the lower GI tract |
WO2017079563A1 (en) | 2015-11-06 | 2017-05-11 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
WO2020261227A1 (en) | 2019-06-26 | 2020-12-30 | Biorchestra Co., Ltd. | Micellar nanoparticles and uses thereof |
JPWO2021221167A1 (de) * | 2020-04-30 | 2021-11-04 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970074A (en) * | 1987-06-29 | 1990-11-13 | Abbott Laboratories | Fluorophores for encapsulation into liposomes |
US5534241A (en) * | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
EP0721328A4 (de) * | 1993-09-27 | 1997-09-17 | Smithkline Beecham Corp | Camptothecin-formulierungen |
NZ318300A (en) * | 1995-09-12 | 1999-08-30 | Liposome Co Inc | Hydrolysis-promoting taxane hydrophobic derivatives |
US20020013282A1 (en) * | 1995-09-26 | 2002-01-31 | John Marshall | Cationic amphipile compositions for interacelluar delivery of therapeutic molecules |
DE19604484C2 (de) * | 1996-02-08 | 2003-10-30 | Peter Edgar Heide | Farbstoffzubereitung zum Markieren von Operationsfeldern in Lebewesen |
EP1037610A4 (de) * | 1997-09-16 | 2004-07-07 | Osi Pharm Inc | Liposomale camptothecin formulierungen |
US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
BR0013866A (pt) * | 1999-09-09 | 2002-05-14 | Univ California | Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos |
JP2004511426A (ja) * | 2000-05-03 | 2004-04-15 | ミュンヘン バイオテク アーゲー | 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬 |
-
2003
- 2003-06-26 EP EP03761520A patent/EP1553924B1/de not_active Expired - Lifetime
- 2003-06-26 AU AU2003249882A patent/AU2003249882B2/en not_active Ceased
- 2003-06-26 JP JP2004548889A patent/JP2005534718A/ja active Pending
- 2003-06-26 CA CA002492080A patent/CA2492080A1/en not_active Abandoned
- 2003-06-26 WO PCT/EP2003/006765 patent/WO2004002455A1/en active Application Filing
- 2003-06-26 DE DE60335279T patent/DE60335279D1/de not_active Expired - Lifetime
- 2003-06-26 AT AT03761520T patent/ATE490763T1/de not_active IP Right Cessation
-
2004
- 2004-12-22 US US11/018,575 patent/US20050181038A1/en not_active Abandoned
-
2009
- 2009-12-22 US US12/654,523 patent/US20100178243A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE490763T1 (de) | 2010-12-15 |
US20050181038A1 (en) | 2005-08-18 |
US20100178243A1 (en) | 2010-07-15 |
WO2004002455A1 (en) | 2004-01-08 |
AU2003249882B2 (en) | 2008-09-18 |
EP1553924A1 (de) | 2005-07-20 |
JP2005534718A (ja) | 2005-11-17 |
EP1553924B1 (de) | 2010-12-08 |
CA2492080A1 (en) | 2004-01-08 |
AU2003249882A1 (en) | 2004-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60335279D1 (de) | Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem | |
DE69920945D1 (de) | Verfahren zur herstellung von arzneistoffpartikeln | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
DE60225561D1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung | |
ATE550015T1 (de) | Verfahren und zusammensetzung zur behandlung von rhinitis | |
ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
ATE482966T1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
BR0315580A (pt) | Derivados de metileno uréia | |
CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
ATE420099T1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
ATE449104T1 (de) | Verfahren zur reinigung von fibrinogen | |
DE60234329D1 (de) | Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2 | |
ATE514718T1 (de) | Peptabody für krebsbehandlung | |
EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
BR0010225A (pt) | Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso | |
ATE407724T1 (de) | Methode zur stimulierung von haarwuchs auf der basis von benzopyranen | |
ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
SE0402507D0 (sv) | Medicinsk lösning, förfarande för framställning och användning därav | |
ATE444754T1 (de) | Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse | |
EA200401462A1 (ru) | Однокамерная система осмотически регулируемой доставки лекарственного средства | |
DE50300920D1 (de) | Ferrocenylliganden und ein verfahren zur herstellung solcher liganden |